Clinical trial
Olmesartan Medoxomil in Hypertension and Renal Impairment
NCT00151827 · Sankyo Pharma Gmbh, Industry · Completed
Key facts
| NCT number | NCT00151827 |
|---|---|
| Title | Olmesartan Medoxomil in Hypertension and Renal Impairment |
| Official title | Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment |
| Lead sponsor | Sankyo Pharma Gmbh, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension, Renal Impairment |
| Intervention type | Drug |
| Interventions | Olmesartan medoxomil, Losartan, Furosemide oral tablets |
| Enrollment | 393 |
| Start date | Aug 1, 2003 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 9, 2005 |
| Last update posted | Oct 14, 2010 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: